Document resource
We report on the exploratory use of the recombinant herpes zoster vaccine (RZV, Shingrix) to manage recurrent genital Herpes Simples Virus (HSV-2) infection in a male patient in his early 60s, with bi-monthly outbreaks causing substantial psychological and physical burden. Genital herpes was confirmed through HSV-2 detection in genital swabs and previously managed with acyclovir, either episodically (400 mg three times a day for 5 days) or continuously (400 mg two times a day). The medical history showed no immunodeficiency or significant comorbidities. VZV IgG status was not measured as this is not routinely assessed during an HSV review.